🔎 Trials Near Me

Home › Mantle Cell Lymphoma › Kansas

Pag-aaral pangklinika para sa Mantle Cell Lymphoma sa Kansas

7 pag-aaral para sa Mantle Cell Lymphoma ang naghahanap ng mga kalahok sa mga site sa Kansas.

Mga Lungsod sa Kansas

Opisyal na teksto ng pag-aaral (English)

BAFFR-targeting CAR T Cells for Patients With Relapsed or Refractory B-NHL

  • University of Kansas Hospital, Kansas City
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Nob 10, 2026 · NCT05370430

A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )

  • University of Kansas Cancer Center, Kansas City
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Nob 4, 2026 · NCT07101328

Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell Lymphoma

  • HaysMed, Hays
  • University of Kansas Cancer Center, Kansas City
  • Lawrence Memorial Hospital, Lawrence
  • at 6 pa
Nagre-recruitPhase 3
Edad 60 pataas · Lahat ng kasarian · Na-update Nob 3, 2026 · NCT05976763

A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers.

  • The University of Kansas Cancer Center, Westwood
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Okt 26, 2026 · NCT06697184

DALY II USA/ MB-CART2019.1 for DLBCL

  • University of Kansas Cancer Center, Westwood
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Hul 13, 2026 · NCT04792489

SynKIR-310 for Relapsed/Refractory B-NHL

  • The University of Kansas Cancer Center, Fairway
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Abr 14, 2026 · NCT06544265

A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies

  • University of Kansas, Westwood
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Nob 14, 2025 · NCT05643742

Mula sa ClinicalTrials.gov, na-kuha noong Nob 15, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.